Selskapet tenker hele tiden på pasientene. Og det er et pluss.
Jeg tolker det på samme måte. Men om de rakk fristen i sommer eller LBA, er vel spørsmålet.
Kan det komme noe mer om Archer, eller var det bare på R&D day?
Edit: Q3 muligens, Vi er jo i qp nå,
En kar som nevnte det på HO:
I disse dager begynner våre to nyansettelser:
Nordic Nanovector appoints Dr Gabriele Elbl as Vice President Global Regulatory Affairs
Nordic Nanovector appoints Dr Lars Nieba as Chief Technology Officer from Bayer AG, where he served as VP and Strategic Product Lead,
3 Likes
skal NANO begynne med Crypto? 
“Nano is a next-generation decentralized network and cryptocurrency designed to solve instantaneous peer-to-peer payments without fees or the need for expensive computational resources.”
Raiblocks ja, tar meg tilbake til januar 2018
1 Like
“Betablockchain”
Da XXL onsdag avholdt den ekstraordinære generalforsamlingen for å stemme gjennom kriseemisjonen i selskapet, valgte Folketrygdfondet å stemme mot flere av forslagene.
Samtidig gjorde fondet klart at det mener det er viktig at XXL-styret påser at minoritetsaksjonærenes interesser «ivaretas når transaksjoner gjennomføres».
«Det er Folketrygdfondets syn at den foreslåtte emisjonen i selskapet medfører en urimelig forskjellsbehandling av minoritetsaksjonærene», heter det i Folketrygdfondets protokollførte forklaring på hvorfor det stemte mot forslagene.
Flott at FF er så bekymret for minoritetsaksjonærene. De kan jo vise at de er sitt ansvar bevist og slutte å låne ut til short i oppstartsselskaper 
7 Likes
29 Likes
Ved eventuelt global nedgangstider hvor store penger trekkes ut av aksjemarkedet. Hvordan utspringer bio-tech sektoren med selskap av type Nano for slike situasjoner.
Hypotese:
Investorer vil alltid søke etter profitt i alle markeder til alle tider men dog ikke like kraftfullt i form av innskutt kapital (en plass må jo de ha pengene).
Kan bio-tech sektoren få en oppsving i form av tilført “ny” kapital fra andre personer som tradisjonelt investerer i andre sektorer? Tenker spesielt på olje og gass investorene som trekker ut størsteparten av pengene sine i sin sektor, men reeinvisterer grader av kapitalen i “spenende” og muliti dobblings kandidater for å “være investert i noe”.
Det er vel en historisk feil konklusjon å tro at risk-off betyr at man kjøpe biotek som tradisjonelt er forbundet med “high risk”. For den gjengse investor på norges oljesmurte børs tror jeg biotek sektoren er det siste de ser på om ting begynner å gå åt skogen… 
1 Like
Når det er risk-off så er det risk-off. Det vil si at kursen gruses enda mer for de som trenger ny finansiering gjennom lån eller emisjoner.
2 Likes
Håper på melding vedr ASH:crossed_fingers:
Jeg håper du ikke blir så skuffet at du selger.
Nope selger ikke, men det hadde virkelig gjort seg med melding før stengetid idag. Evig optimist😅
1 Like
Kommer det en melding i dag så kjøper jeg en halv børspost som en gave til meg selv 
2574 The Dual Cell Cycle Kinase Inhibitor JNJ-7706621 Reverses Resistance to CD37 Targeted Radioimmunotherapy in Activated B Cell like Diffuse Large B Cell Lymphoma Cell Lines
Program: Oral and Poster Abstracts
Session: 605. Molecular Pharmacology, Drug Resistance—Lymphoid and Other Diseases: Poster II
Hematology Disease Topics & Pathways:
antibodies, Biological, Diseases, cell division, drug-drug interaction, Non-Biological, Therapies, Combinations, Biological Processes, chemotherapy, Non-Hodgkin Lymphoma, DNA damage, B-Cell Lymphoma, DLBCL, immunotherapy, Lymphoid Malignancies
Sunday, December 8, 2019, 6:00 PM-8:00 PM
Hall B, Level 2 (Orange County Convention Center)
Gro Elise Rødland, PhD1*, Katrine Melhus2*, Roman Generalov2*, Sania Gilani1*, Francesco Bertoni, MD3, Jostein Dahle, PhD2*, Randi Syljuåsen, PhD1* and Sebastian Patzke, PhD 1,2*
1Institute for Cancer Research / Radiation Biology, OUH Norwegian Radium Hospital, Oslo, Norway
2Research & Development, Nordic Nanovector ASA, Oslo, Norway
3Università della Svizzera italiana, Institute of Oncology Research, Bellinzona, Switzerland
The CD37 targeting radioimmunoconjugate 177Lu-lilotomab satetraxetan (Betalutin®) is currently being evaluated as monotherapy in a clinical phase 2b trial for patients with follicular lymphoma (FL) and in a phase 1 trial for patients with diffuse large B-cell lymphoma (DLBCL), as well as in a phase 1b trial in combination with rituximab for patients with relapsed/refractory FL. Herein we have investigated the effect of 177Lu-lilotomab satetraxetan in seven activated B-cell like (ABC) DLBCL cell lines. Although the radioimmunoconjugate showed anti-tumor activity, primary resistance was observed in a subset of cell lines: U-2932 and RIVA. Both cell lines are representative for TP53 deficient Double Expressor (DE) DLBCL. Importantly, resistance was not a consequence of reduced binding of the radioimmunoconjugate to cell surface expressed CD37. Thus, we set out to identify drugs able to overcome the resistance to 177Lu-lilotomab satetraxetan in both resistant ABC-DLBCL cell lines. We performed a viability-based screen combining 177Lu-lilotomab satetraxetan with the 384-compound Cambridge Cancer Compound Library. Drug combinations were scored using Bliss and Chou-Talalay algorithms. We identified and characterized the dual-specific CDK1/2 and AURA/B kinase inhibitor JNJ-7706621 as compound able to revert the resistance to radioimmunotherapy (RIT), alongside topoisomerase and histone deacetylases (HDAC) inhibitors.
Kinetic studies of the effect of mono- and combination therapy of U-2932 and RIVA cells with JNJ-7706621 and 177Lu-lilotomab satetraxetan are suggestive of a model in which radiation damage induced G2-arrested lymphoma cells eventually enter mitosis (repair or escape) and mitotic entry, progression and exit are impaired by JNJ-7706621 mediated inhibition of CDK1/2 and AURKA/B. Extended residence-time of cells in mitosis due to chromosome condensation and congression defects as well as spindle and mid-spindle assembly failure is likely pivotal for the increased sensitivity to persistent 177Lu-lilotomab satetraxetan deposited DNA damage, ultimately promoting cytokinesis failure (multinucleation, aneuploidy, increased cell size) and cell death.
In conclusion, CD37-targeting 177Lu-lilotomab satetraxetan RIT showed activity in several ABC-DLBCL lymphoma cell lines. CD37-independent RIT-resistance was identified in two cell lines representative of aggressive DE ABC-DLBCLs with inactive TP53, and reversed by subsequent inhibition of CDK1/2 and AURKA/B by JNJ-7706621. These findings may be of potential relevance for ongoing clinical trials of 177Lu-lilotomab satetraxetan in relapsed, ASCT-non-eligible DLBCL, and may also be more generally applicable to other 177Lu-based RITs and alternative radionuclide utilizing targeted therapies. Future pre-clinical investigations are required to elucidate the potential application of CDK1/2 and AURKA/B inhibitors as a strategy to revert RIT resistance in TP53 deficient cancers.
Disclosures: Rødland: Nordic Nanovector ASA: Patents & Royalties, Research Funding. Melhus: Nordic Nanovector ASA: Employment, Equity Ownership, Patents & Royalties. Generalov: Nordic Nanovector ASA: Employment, Equity Ownership, Patents & Royalties. Bertoni: Nordic Nanovector ASA: Research Funding; Oncology Therapeutic Development: Research Funding; PIQUR Therapeutics AG: Other: travel grant, Research Funding; HTG: Other: Expert Statements ; Amgen: Other: travel grants; Astra Zeneca: Other: travel grants; Jazz Pharmaceuticals: Other: travel grants; NEOMED Therapeutics 1: Research Funding; Acerta: Research Funding; ADC Therapeutics: Research Funding; Bayer AG: Research Funding; Cellestia: Research Funding; CTI Life Sciences: Research Funding; EMD Serono: Research Funding; Helsinn: Consultancy, Research Funding; ImmunoGen: Research Funding; Menarini Ricerche: Consultancy, Research Funding. Dahle: Nordic Nanovector ASA: Employment, Equity Ownership, Patents & Royalties. Syljuåsen: Nordic Nanovector ASA: Patents & Royalties, Research Funding. Patzke: Nordic Nanovector ASA: Employment, Patents & Royalties.
28 Likes
Ved første øyekast kan det jo virke litt negativt at to cellelinjer er resistente, men at det bare er to og at de har funnet en metode å omgå resistensen på er jo bare helt fantastisk!!!
3 Likes
Det vil si at de har fått et late breaking abstract til ASH?
Abstract. “Abstracts posted online November 6, 2019, 9:00 a.m. Eastern time”
“Late-breaking abstracts posted online November 21, 2019, 9:00 a.m. Eastern time”